Even before JAK2-V617F was discovered as a genetic driver of MPN, it had been demonstrated, that forced expression of TPO via retroviral expression or hypomorphic mutants in GATA1 were sufficient to cause fibroblast activation and myelofibrosis in mice [241–243]. Here, JAK2 is linked to myeloproliferative disorder.